Related Experiment Video

Updated: Jun 18, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer

Zhiyong Liao1, Jacqueline Lutz, Marja T Nevalainen

  • 1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, Philadelphia, PA 19107, USA.

The International Journal of Biochemistry & Cell Biology
|November 17, 2009
PubMed

Insights

Prostate cancer often becomes resistant to hormone therapy and spreads. Targeting transcription factor Stat5 signaling offers a promising therapeutic strategy for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer is a leading cause of cancer death in Western males, frequently progressing to castration-resistant and metastatic disease.
  • Current treatments for advanced prostate cancer offer limited survival benefits, highlighting the need for novel therapeutic approaches.
  • The majority of prostate cancer deaths result from castration-resistant growth and metastasis.

Purpose of the Study:

  • To review the critical role of Signal Transducer and Activator of Transcription 5 (Stat5) signaling in prostate cancer development and progression.
  • To explore the molecular mechanisms underlying Stat5a/b activity in prostate cancer.
  • To discuss the potential of Stat5a/b inhibition as a therapeutic strategy for managing advanced prostate cancer.

Main Methods:

  • Literature review of existing research on prostate cancer, castration resistance, metastasis, and Stat5 signaling pathways.
  • Analysis of molecular mechanisms involving Stat5a and Stat5b in prostate cancer pathogenesis.
  • Synthesis of data to evaluate Stat5 inhibition as a viable therapeutic option.

Main Results:

  • Stat5 signaling is implicated in the pathogenesis and progression of prostate cancer.
  • Stat5a and Stat5b play significant roles in driving castration-resistant growth and metastasis.
  • Inhibition of Stat5a/b may represent a novel therapeutic avenue for patients with advanced prostate cancer.

Conclusions:

  • Stat5 signaling is a key driver in the progression of prostate cancer to a lethal, castration-resistant state.
  • Targeting Stat5a/b offers a promising molecular strategy to overcome therapeutic resistance and improve patient survival.
  • Further research into Stat5 inhibition is warranted for the development of effective treatments for advanced prostate cancer.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...